Allergan (NYSE: AGN) said today that it closed its $300 million, all-cash acquisition of AqueSys and its Xen soft glaucoma stent, in a deal that also includes unspecified milestone payments. The device made by Aliso Viejo, Calif.-based AqueSys is designed to treat glaucoma by shunting intra-ocular fluid from the anterior chamber of the eye into the sub-conjunctival […]
AqueSys
Allergan to drop $300m on AqueSys
Allergan (NYSE: AGN) last week said it agreed to pay $300 million plus milestones to acquire AqueSys and its Xen soft glaucoma stent in an all-cash deal. The device made by Aliso Viejo, Calif.-based AqueSys is designed to treat glaucoma by shunting intra-ocular fluid from the anterior chamber of the eye into the sub-conjunctival space. The […]
AqueSys raises $43.6M and closes U.S. trial of XEN Gel glaucoma stent
California ophthalmic devices maker AqueSys touted a couple of milestones today, landing a successful $43.6 million Series D funding round and closing enrollment in U.S. clinical trial of its XEN Gel stent for treatment of glaucoma.
The funding will allow AqueSys to make progress with its clinical trials, regulatory pursuits and commercialization efforts, president & CEO Ron Bache said in prepared remarks.
